Complement C5a potentiates uric acid crystal-induced IL-1β production

European Journal of Immunology

Volumn 44, Issue 12, 2014, Pages 3669-3679

  An, Ling Ling ^a   Mehta, Payal ^a   Xu, Linda ^a   Turman, Sean ^a   Reimer, Thornik ^a   Naiman, Brian ^a   Connor, Jane ^a   Sanjuan, Miguel ^a   Kolbeck, Roland ^a   Fung, Michael ^a  

^a MEDIMMUNE   (United States)

Author keywords

C5a; Gout; IL 1 ; Inflammasome; monosodium urate ; uric acid (MSU) crystal; Priming

Indexed keywords

CALCIUM ION; CATHEPSIN B; CHEMOKINE; CHOLESTEROL; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5A RECEPTOR; CYTOKINE; ECULIZUMAB; INFLAMMASOME; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA ANTIBODY; INTERLEUKIN 1BETA CONVERTING ENZYME; POTASSIUM ION; REACTIVE OXYGEN METABOLITE; URATE; URIC ACID; ANTIOXIDANT; CALCIUM; IL1B PROTEIN, HUMAN; POTASSIUM;

ARTICLE; BLOOD; CALCIUM CELL LEVEL; CALCIUM MOBILIZATION; CELL VIABILITY; COMPLEMENT ACTIVATION; CONTROLLED STUDY; CRYSTAL; CYTOKINE PRODUCTION; ENZYME ACTIVITY; EX VIVO STUDY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; INFLAMMATION; MONOCYTE; NORMAL HUMAN; PHAGOCYTOSIS; POTASSIUM TRANSPORT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; CALCIUM SIGNALING; CLINICAL TRIAL; DRUG EFFECTS; FEMALE; IMMUNOLOGY; MALE; PATHOLOGY;

ANTIOXIDANTS; CALCIUM; CALCIUM SIGNALING; CASPASE 1; COMPLEMENT C5A; FEMALE; HUMANS; INFLAMMASOMES; INTERLEUKIN-1BETA; MALE; MONOCYTES; POTASSIUM; URIC ACID;

EID: 84923607878     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201444560     Document Type: Article

References (43)

1. Horvath, G. L., Schrum, J. E., De Nardo, C. M. and Latz, E., Intracellular sensing ofmicrobes and danger signals by the inflammasomes. Immunol. Rev. 2011. 243: 119-135.
2. Martinon, F., Mayor, A. and Tschopp, J., The inflammasomes: guardians of the body. Annu. Rev. Immunol. 2009. 27: 229-265.
3. Martinon, F., Petrilli, V., Mayor, A., Tardivel, A. and Tschopp, J., Goutassociated uric acid crystals activate the NALP3 inflammasome. Nature 2006. 440: 237-241.
4. Chen, C. J., Shi, Y., Hearn, A., Fitzgerald, K., Golenbock, D., Reed, G., Akira, S. et al., MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals. J. Clin. Invest. 2006. 116: 2262-2271.
5. Rajamaki, K., Lappalainen, J., Oorni, K., Valimaki, E., Matikainen, S., Kovanen, P. T., Eklund, K. K. et al., Cholesterol crystals activate the NLRP3 inflammasome in humanmacrophages: a novel link between cholesterol metabolism and inflammation. PLoS One 2010. 5:e11765.
6. Duewell, P., Kono, H., Rayner, K. J., Sirois, C. M., Vladimer, G., Bauernfeind, F. G., Abela, G. S. et al., NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010. 464: 1357-1361.
7. Wen, H., Gris, D., Lei, Y., Jha, S., Zhang, L., Huang, M. T-H., Brickey, W. J. et al., Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat. Immunol. 2011. 12: 408-415.
8. Vandanmagsar, B., Youm, Y. H., Ravussin, A., Galgani, J. E., Stadler, K., Mynatt, R. L., Ravussin, E. et al., The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat. Med. 2011. 17: 179-188.
9. Heneka, M. T., Kummer, M. P., Stutz, A., Delekate, A., Schwartz, S., Vieira-Saecker, A., Griep, A. et al., NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature 2013. 493: 674-678.
10. Halle, A., Hornung, V., Petzold, G. C., Stewart, C. R., Monks, B. G., Reinheckel, T., Fitzgerald, K. A. et al., The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat. Immunol. 2008. 9: 857-865.
11. Schumacher, H. R., Jr., Evans, R. R., Saag, K. G., Clower, J., Jennings, W., Weinstein, S. P., Yancopoulos, G. D. et al., Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebocontrolled, confirmatory efficacy study. Arthritis Care Res. 2012. 64: 1462-1470.
12. So, A., De Meulemeester, M., Pikhlak, A., Yucel, A. E., Richard, D., Murphy, V., Arulmani, U. et al., Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study. Arthritis Rheum. 2010. 62: 3064-3076.
13. Busso, N. and So, A., Mechanisms of inflammation in gout. Arthritis Res. Ther. 2010. 12: 206-213.
14. Doherty, M., Whicher, J. T. and Dieppe, P. A., Activation of the alternative pathway of complement by monosodium urate monohydrate crystals and other inflammatory particles. Ann. Rheum. Dis. 1983. 42: 285-291.
15. Tramontini, N., Huber, C., Liu-Bryan, R., Terkeltaub, R. A. and Kilgore, K. S., Central role of complement membrane attack complex in monosodium urate crystal-induced neutrophilic rabbit knee synovitis. Arthritis Rheum. 2004. 50: 2633-2639.
16. Naff, G. B. and Byers, P. H., Complement as a mediator of inflammation in acute gouty arthritis. I. studies on the reaction between human serum complement and sodium urate crystals. J. Lab. Clin. Med. 1973. 81: 747-760.
17. Ward, P. A., The harmful role of C5a on innate immunity in sepsis. J. Innate Immun. 2010. 2: 439-445.
18. Ibrahim, F. B. M., Pang, S. J. and Melendez, A. J., Anaphylatoxin signaling in human neutrophils: a key role for sphingosine kinase. J. Biol. Chem. 2004. 279: 44802-44811.
19. Gross, V. and Andus, T., Human recombinant C5a enhances lipopolysaccharide-induced synthesis of interleukin-6 by human monocytes. Eur. J. Clin. Invest. 1992. 22: 271-276.
20. Weaver, D. J., Jr., Reis1, E. S., Pandey, M. K., Köhl, G., Harris, N., Gerard, C. and Köhl, J., C5a receptor-deficient dendritic cells promote induction of treg and Th17 cells. Eur. J. Immunol. 2010. 40: 710-721.
21. 2+ fluxes leading to NLRP3 inflammasome activation. J. Cell. Sci. 2013. 126: 2903-2913.
22. Laudisi, F., Spreafico, R., Evrard, M., Hughes, T. R., Mandriani, B., Kandasamy, M., Morgan, B. P. et al., Cutting edge: the NLRP3 inflammasome links complement-mediated inflammation and IL-1beta release. J. Immunol. 2013. 191: 1006-1010.
23. Samstad, E. O., Niyonzima, N., Nymo, S, Aune, M. H., Ryan, L., Siril, S., Bakke, S. S. et al., Cholesterol crystals induce complement-dependent inflammasome activation and cytokine release. J. Immunol. 2014. 192: 2837-2845.
24. Mollnes, T. E., Brekke, O-L., Fung, M., Fure, H., Christiansen, D., Bergseth, G., Videm, V. et al., Essential role of the C5a receptor in E. coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood 2002. 100: 1869-1877.
25. Scanu, A., Oliviero, F., Ramonda, R., Frallonardo, P., Dayer, J. M. and Punzi, L., Cytokine levels in human synovial fluid during the different stages of acute gout: role of transforming growth factor beta1 in the resolution phase. Ann. Rheum. Dis. 2012. 71: 621-624.
26. Hiscott, J., Marois, J., Garoufalis, J., D'addario, M., Roulston, A., Kwan, I., Pepin, N. et al., Characterization of a functional NF-kappa B site in the human interleukin 1 beta promoter: evidence for a positive autoregulatory loop. Mol. Cell. Biol. 1993. 13: 6231-6240.
27. Lappegard, K. T., Fung, M., Bergseth, G., Riesenfeld, J. and Mollnes, T. E., Artificial surface-induced cytokine synthesis: effect of heparin coating and complement inhibition. Ann. Thorac. Surg. 2004. 78: 38-44.
28. Hwang, J. I., Fraser, I. D., Choi, S., Qin, X. F. and Simon, M. I., Analysis of C5a-mediated chemotaxis by lentiviral delivery of small interfering RNA. Proc. Natl. Acad. Sci. USA 2004. 101: 488-493.
29. Netea, M. G., Nold-Petry, C. A., Nold, M. F., Joosten, L. A. B., Opitz, B., van derMeer, J. H. M., van de Veerdonket, F. L. et al., Differential requirement for the activation of the inflammasome for processing and release of IL-1beta in monocytes and macrophages. Blood 2009. 113: 2324-2335.
30. Martinon, F., Signaling by ROS drives inflammasome activation. Eur. J. Immunol. 2010. 40: 595-653.
31. 2+ and cAMP. Nature 2012. 492: 123-127.
32. Goldstein, I., Fontaliran, F., Marie, F. N. and Gay, J., Presence of immunoglobulins and complement in the walls of the coronary arteries in atherosclerosis. Pathol. Biol. 1986. 34: 841-846.
33. (+) efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter. Immunity 2013. 38: 1142-1153.
34. van der Veena, R. C., Dietlina, T. A., Karapetian, A., Holland, S. M. and Hofman, F. M., Extra-cellular superoxide promotes T cell expansion through inactivation of nitric oxide. J. Neuroimmunol. 2004. 153: 183-189.
35. Fields, T. R., Abramson, S. B., Weissmann, G., Kaplan, A. P. and Ghebrehiwet, B., Activation of the alternative pathway of complement by monosodium urate crystals. Clin. Immunol. Immunopathol. 1983. 26: 249-257.
36. Scieszka, J. F., Maggiora, L. L., Wright, S. D. and Cho, M. J., Role of complements C3 and C5 in the phagocytosis of liposomes by human neutrophils. Pharm. Res. 1991. 8: 65-69.
37. Sharma, G., Valenta, D. T., Altman, Y., Harvey, S., Xie, X., Mitragotri, S. and Smith, J. W., Polymer particle shape independently influences binding and internalization by macrophages. J. Control. Release 2010. 147: 408-412.
38. van der Goes, A., Brouwer, J., Hoekstra, K., Roos, D., van den Berg, T. K. and Dijkstra, C. D., Reactive oxygen species are required for the phagocytosis of myelin by macrophages. J. Neuroimmunol. 1998. 92: 67-75.
39. Ward, P. A., The dark side of C5a in sepsis. Nat. Rev. Immunol. 2004. 4: 133-142.
40. Bauernfeind, F., Bartok, E., Riege, A., Franchi, L., Nunez, G. and Hornung, V., Reactive oxygen species inhibitors block priming, but not activation, of the NLRP3 inflammasome. J. Immunol. 2011. 187: 613-617.
41. Giamarellos-Bourboulis, E. J., Mouktaroudi, M., Bodar, E., van der Ven, J., Kullberg, B-J., Netea, M. G. and van der Meer, J. W. M., Crystals of monosodium urate monohydrate enhance lipopolysaccharide-induced release of interleukin 1 beta by mononuclear cells through a caspase 1-mediated process. Ann. Rheum. Dis. 2009. 68: 273-278.
42. Fung, M., Lu, M., Fure, H., Sun, W., Sun, C., Shi, N. Y., Dou, Y. et al., Pre-neutralization of C5a-mediated effects by the monoclonal antibody 137-26 reacting with the C5a moiety of native C5 without preventing C5 cleavage. Clin. Exp. Immunol. 2003. 133: 160-169.
43. Liu-Bryan, R., Scott, P., Sydlaske, A., Rose, D. M. and Terkeltaub, R., Innate immunity conferred by toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal-induced inflammation. Arthritis Rheum. 2004. 52: 2936-2946.